Moderna's Bet on the Next Pandemic Just Entered the Final Round
Moderna just launched the world's first Phase 3 trial of an mRNA bird flu vaccine, right as H5N1 creeps closer to becoming a human problem. But the U.S. government already pulled $766 million in funding, so who's actually paying for this pandemic insurance policy?
The Insurance Policy Nobody Wants to Cash In
Somewhere in a community clinic in England, a healthy adult just rolled up their sleeve and got injected with what might be the world's most important insurance policy. Moderna is preparing for a Phase 3 trial of its mRNA-based H5N1 bird flu vaccine, called mRNA-1018, across the United States and United Kingdom, with the first participants dosed in April 2026. It's the world's first pivotal late-stage trial of an mRNA vaccine designed specifically for a potential influenza pandemic.
The timing isn't random. Bird flu has been quietly creeping closer to becoming everyone's problem.
Why Bird Flu Keeps Showing Up in Headlines
H5N1 avian influenza has been tearing through American agriculture like nothing we've seen before. By mid-2025, the virus had infected roughly 1,075 dairy herds across 17 states. It had been detected in poultry in all 50 states.
And it hasn't stayed in animals. Since March 2024, the U.S. has recorded about 70 confirmed human H5N1 infections, mostly in dairy and poultry workers. One person died. Most cases were mild (think pink eye and sniffles), but that's cold comfort when you understand the real fear: every time this virus jumps into a mammal, it gets another lottery ticket for the mutation that could make it spread easily between people.
Think of it like a burglar rattling doorknobs on every house in the neighborhood. Most doors are locked. But he's trying a lot of doors.
The CDC still rates the risk to the general public as low. For people working on farms and around infected animals, though, the risk is moderate to high. And public health experts worry about what they can't see: mild or symptom-free infections that never get tested, quietly giving the virus more chances to adapt.
What Moderna Is Actually Testing
The Phase 3 trial is enrolling about 4,000 healthy adults aged 18 and older. Roughly 75% of participants will come from the UK (across 26 community clinic sites in England and Scotland), with the rest in the U.S. The study uses a classic design: randomized, placebo-controlled, triple-blinded. Nobody knows who got the real thing, not even the doctors running the trial.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Participants receive two doses of mRNA-1018 via intramuscular injection. The primary goals are straightforward: is it safe, and does it trigger a strong immune response against H5N1?
Notice what's not on that list. This trial isn't measuring whether the vaccine prevents actual bird flu infections in the wild, because thankfully, H5N1 isn't spreading between humans yet. Instead, Moderna is building the blueprint now so that if the virus does go pandemic, regulators already have a thick safety and immunogenicity file sitting on their desks.
The Early Data That Got Them Here
Moderna didn't jump straight to Phase 3 on a hunch. Earlier Phase 1/2 trials enrolled about 1,500 adults across multiple H5 and H7 vaccine candidates at varying doses. The results were genuinely encouraging.
After just one dose, roughly 80% of participants developed protective antibody levels (measured by a standard blood test called HAI, where a titer of 1:40 or above is considered protective). After the second dose, that number climbed to nearly 98%. Six months later, about 71% still had protective levels, which is impressive durability for a pandemic vaccine you'd need to deploy fast and have last through a crisis.
On safety, the profile looked a lot like what you'd expect from an mRNA shot: injection-site pain, fatigue, headache. Almost all reactions were mild to moderate. Severe reactions occurred in fewer than 5% of participants, with no Grade 4 (life-threatening) events. One serious adverse event, a fainting episode, was reported.
In other words, the earlier trials checked every box you'd want checked before spending the money on a massive Phase 3.
Follow the Money (It Gets Complicated)
This is where the story takes an interesting turn. The trial is backed by up to $54.3 million from CEPI, the Coalition for Epidemic Preparedness Innovations. In exchange, Moderna has pledged to reserve 20% of its H5 pandemic vaccine manufacturing capacity for low- and middle-income countries at affordable prices. It's a direct response to the vaccine hoarding fiasco of COVID-19.
But the U.S. government side of the ledger tells a different story. BARDA, the federal agency that funds pandemic preparedness, had originally committed a combined $766 million to Moderna for H5N1 and pandemic flu vaccine development. Both contracts were cancelled in mid-2025. HHS said the project "failed to satisfy the scientific and safety criteria" for continued support, and the administration announced a broader pullback from mRNA vaccine investments entirely.
A Moderna spokesperson confirmed: the company currently has no active collaboration with BARDA.
So Moderna is running this pivotal trial without U.S. government backing, leaning instead on CEPI funding and its own resources. The UK facility at Harwell, capable of producing 100 million doses per year (scalable to 250 million in a pandemic), gives the company a manufacturing foothold that doesn't depend on Washington's mood.
A Crowded Race With High Stakes
Moderna isn't alone in preparing for a potential H5N1 pandemic. CSL Seqirus already has FDA-approved AUDENZ sitting in the U.S. national stockpile. GSK has Arepanrix, with Canada procuring 500,000 doses for early deployment. Sanofi maintains a legacy egg-based H5N1 vaccine in stockpiles dating back to 2007. And Pfizer reportedly has its own mRNA H5N1 candidate in Phase 1.
The traditional vaccines have a head start in licensing and stockpiling, but they're based on older technology that's slower to update when the virus mutates. mRNA's selling point is speed: you can redesign the vaccine to match a new strain in weeks, not months. That advantage is exactly what made mRNA the hero of COVID-19, and it's the same pitch Moderna is making now.
The Bottom Line: Expensive Insurance, Priceless If You Need It
Analysts tend to frame Moderna's H5 program the same way: high optionality, asymmetric upside. If bird flu never becomes a human pandemic, mRNA-1018 is a line item on a balance sheet; important for preparedness, but not a revenue blockbuster. If H5N1 does make the jump to efficient human-to-human spread, a licensed mRNA vaccine that can be updated and scaled fast becomes one of the most valuable products on earth.
The meaningful revenue, analysts note, is likely "several years away" and depends on government procurement, regulatory approvals, and whether the virus cooperates with anyone's business model.
For now, Moderna is placing a bet that the world learned something from COVID-19: you don't wait for the fire to start before buying a fire extinguisher. Whether governments are willing to pay for that extinguisher in advance is a separate question entirely.
Clinical & Regulatory4 min read
The Best-Selling Drug Just Met Its Copycat
Samsung Bioepis just posted the first-ever Phase 3 data for a Keytruda copycat, and it matched the $32 billion original on every measure. With at least ten companies racing to build biosimilar versions of the world's best-selling drug, the countdown to cheaper cancer immunotherapy has officially begun.
